Dupilumab Effective in PPI-Refractory Pediatric EoE
Excellent news for more youthful kids experiencing the unusual however devastating intestinal condition eosinophilic esophagitis (EoE). A randomized placebo-controlled research study discovered the monoclonal antibody dupilumab (Dupixent) resulted in histologic remission in considerably more afflicted kids than placebo. Information from this trial resulted in a January United States Food and Drug Administration (FDA) approval of the anti-inflammatory biologic for clients aged 1-11 years weighing a minimum of 15 kg.Mirna Chehade, MD, MPHIn addition, the trial, released in The New England Journal of Medicinediscovered that a higher-exposure dupilumab routine enhanced crucial secondary endpoints, according to gastroenterologist Mirna Chehade, MD, MPH, a teacher of pediatrics at Icahn School o...